Arunogiri Shalini, Keks Nicholas A, Hope Judy
Turning Point, Eastern Health and Eastern Health Clinical School, Monash University, Fitzroy, VIC, Australia
Monash University and Centre of Mental Health Education and Research at Delmont Private Hospital, Melbourne, VIC, Australia.
Australas Psychiatry. 2016 Aug;24(4):381-4. doi: 10.1177/1039856216629839. Epub 2016 Feb 5.
There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression.
Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years. However, there remain many unanswered questions regarding its effectiveness, safety, and the route, dose and regimen for repeated administration. Experts have also raised concerns regarding ketamine's adverse effects, abuse potential and the risk of addiction. At this stage, the use of ketamine in the treatment of depression remains in the realm of research settings.
公众和媒体对氯胺酮作为抑郁症新型治疗方法的潜力广泛关注。本文综述当前证据是否支持氯胺酮用于抑郁症的临床治疗。
在过去15年中，临床试验研究了静脉注射氯胺酮治疗抑郁症状的情况。然而，关于其有效性、安全性以及重复给药的途径、剂量和方案仍有许多未解答的问题。专家们也对氯胺酮的不良反应、滥用可能性和成瘾风险表示担忧。现阶段，氯胺酮用于治疗抑郁症仍处于研究阶段。
